Skip to content

Majority Press

 Expand
Skip to page number selection

Press releases from: July 2017

Published
Judiciary Committee Announces Hearing, Sends Invitations, Requests Documents
Published
Grassley Seeks More Information on Pro-Russia Lobbyist Present at Trump, Jr. Meeting
Published
Grassley, Durbin: More Temporary Work Visas Harm American Workers
Published
Grassley Raises Concerns over Dramatic Rise in Specialty Visa Applications
Published
Grassley Statement at Executive Business Meeting
Published
Grassley Statement at Hearing on FBI Director Nominee
Published
Grassley Statement for Subcommittee on Border Security and Immigration Hearing on Visa Overstays
Published
Grassley Seeks Visa and Parole Information on Russian Lawyer’s Travel to United States
Published
Expired Body Armor, Inconsistent Training Raises Risks for Marshals
Published
Grassley, Coons Question USPTO Participation in Commerce’s “Enterprise Services” Initiative

Press releases from: June 2017

Published
Grassley Statement at Executive Business Meeting
Published
Grassley Blasts Obama Administration Justice Department for Handling of Sexual Misconduct, Calls on Trump Administration to Make Changes
Published
VIDEO: Grassley Meets with FBI Director Nominee Christopher Wray
Published
Grassley, Graham Seek Surveillance Applications in Russia Probe
Published
National Security Briefing Shuttered by Democrat Obstruction
Published
Grassley Statement at a Hearing on Reauthorizing America’s Vital National Security Authority and Protecting Privacy and Civil Liberties
Published
Grassley Statement at a Hearing on Reauthorizing America’s Vital National Security Authority and Protecting Privacy and Civil Liberties
Published
Grassley Comments on Supreme Court’s Actions to Reinstate the President’s Ability to Strengthen our National Security
Published
Grassley Supports FDA Steps to Improve Access to Less Costly Medications
Published
Grassley Joins Klobuchar, Bipartisan Group of Senate Judiciary Committee Members to Urge FDA Commissioner to Address Abuses in the Regulatory Process that Delay Competition and Increase Prescription Drug Costs